What Does Biodesix (BDSX) Do? – A Complete Look at Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters

Company overview

What Does Biodesix (BDSX) Do? – A Complete Look at Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters

Updated June 26, 2026 · First published April 17, 2026

Biodesix (BDSX) is a US molecular diagnostics company specialized in blood-based diagnostics for lung nodules and lung cancer. Lung diagnostic revenue growth and the narrowing of operating losses are the core drivers of the stock. As a small-cap growth name, it warrants a combined look at earnings, outlook, and peer/related-stock trends.

🏢 What kind of company is Biodesix?

Biodesix (BDSX) is a US-headquartered molecular diagnostics company focused on lung disease diagnostics. It develops and provides blood-based testing solutions that support the early identification of lung nodules and lung cancer, with precision diagnostics in lung health at the core of its identity.

Its key business is a portfolio of blood tests that help assess lung nodule risk and diagnose lung cancer. It also offers biomarker analysis services for pharmaceutical and biotech companies, establishing itself as a specialty diagnostics provider in the lung diagnostic space.

How does Biodesix make money?

Business Segment	Revenue Contribution	Description
Lung Diagnostics	Core	Revenue from blood-based lung nodule and lung cancer diagnostic tests
Biopharma Services	Expanding	Biomarker analysis and clinical support for pharmaceutical companies

The lung diagnostics segment accounts for the bulk of revenue, and a double-digit revenue growth trend is continuing on the back of rising test volumes. The biopharma services segment acts as a complementary diversification pillar, partially smoothing out the cyclical swings of diagnostic test revenue. Gross margin is trending higher on scale efficiencies from increased test volume, but the operating-level profile remains in a loss-making growth phase, making the pace of loss reduction the key metric to watch.

📐 Biodesix market cap and company scale

Market capitalization stands at $274.8M, and headcount is 334 people.

It is a small-cap molecular diagnostics name focused on lung diagnostics, with broader adoption of its diagnostic tests serving as its core growth lever. It is often compared with peers in the same molecular and genetic diagnostics space such as VCYT and GH, though its market cap sits well below those larger diagnostics players. Still in a pre-profit growth phase, the company channels resources toward revenue growth and operating efficiency rather than capital returns.

📈 Biodesix outlook and stock trends

1-Year Price Performance

Analyst Consensus

1.0

Sell Hold Strong Buy

Target Price $34 +30.6% Current $26

52-Week Price Range

$26

Low $5 High $31

vs. low +395.06% vs. high -16.83%

Rising demand for early lung nodule and lung cancer diagnostics and growing test adoption are the key medium- to long-term growth drivers. The accumulation of clinical evidence for blood-based testing and the expansion of reimbursement coverage will set the pace of revenue growth, while the biopharma services segment also contributes to revenue diversification. In the near term, the continuation of operating losses, the rate of cash burn, and reimbursement negotiation outcomes could act as sources of volatility, and intensifying competition with larger diagnostics players remains a risk on the market-share front.

Broader adoption of early lung nodule and lung cancer diagnostic tests
Expansion of reimbursement coverage
Growth of the biopharma services segment

⚔️ Biodesix core strengths and risks

A lung-focused diagnostic portfolio and steady test revenue growth are the company's strengths, while continued operating losses and competition with larger rivals are the core risks.

💪 Core Strengths

Lung Diagnostics Focus

By concentrating on blood-based diagnostics for lung nodules and lung cancer, the company holds a differentiated test portfolio in a specific clinical area.

Test Revenue Growth

Driven by rising lung diagnostic test volumes, revenue continues to post double-digit growth.

Revenue Diversification

Beyond diagnostic tests, biomarker analysis services for pharmaceutical companies spread out the revenue base.

⚠️ Core Risks

Sustained Operating Losses

As a growth-stage company, operating losses continue, creating cash burn and funding risks.

Intensifying Competition

Competition with larger diagnostics players such as VCYT exposes the company to pressure on share and pricing.

Reimbursement Uncertainty

Diagnostic test revenue is highly dependent on reimbursement coverage and negotiation outcomes.

🔄 Biodesix competitors and related (beneficiary) stocks

Direct competitors include VCYT in lung cancer genetic diagnostics, GH in liquid-biopsy cancer diagnostics, and MYGN in genetic diagnostic testing. As a related name, NTRA, which focuses on prenatal and oncology genetic testing, is grouped under the same molecular diagnostics theme, moving in tandem with the broader expansion of precision diagnostics markets including lung diagnostics.

Competitors

Ticker	Company	Price	Change	Market Cap	P/E	PBR	ROE	Dividend Yield
VCYT	Veracyte Inc	$42.03	-4.2%	$3.4B	29.8	2.4	8.77%	-
GH	Guardant Health Inc	$159.03	-2.3%	$21.3B	-	-	-	-
MYGN	Myriad Genetics Inc	$3.36	+5.3%	$321.4M	-	1.1	-32.54%	-

Related stocks (beneficiaries)

Ticker	Company	Price	Change	Market Cap	P/E	PBR	ROE	Dividend Yield
NTRA	Natera Inc	$326.14	-1.3%	$47.0B	-	25.7	-12.54%	-

Checklist Item	What to Check	Current Status
Lung Diagnostic Growth	Trend in lung diagnostic test volume and revenue growth	Double-digit growth trend
Profitability Improvement	Operating loss reduction and cash burn pace	Loss-narrowing phase
Reimbursement	Expansion of reimbursement coverage by test	Gradual expansion
Financial Health	Cash position and funding capacity	Warrants monitoring